Search

Your search keyword '"Flohr C"' showing total 665 results
Start Over Author "Flohr C"
665 results on '"Flohr C"'

2. 201 Bone safety data in adolescents with moderate-to-severe atopic dermatitis treated with abrocitinib: interim results from the JADE EXTEND MRI substudy

Author

Zdybski, J., primary, Wollenberg, A., additional, Flohr, C., additional, Brunner, P.M., additional, Högler, W., additional, Egeberg, A., additional, Irvine, A.D., additional, Fan, H., additional, Biswas, P., additional, Radi, Z., additional, Farooqui, S.A., additional, Koppensteiner, H., additional, Sherlock, S.P., additional, and Chan, G., additional

Published
2023
Full Text
View/download PDF

4. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in Sub‐Saharan Africa?

Author

Schmid‐Grendelmeier, P., primary, Rabenja, F. Rapelanoro, additional, Beshah, A. M., additional, Ball, M. D., additional, Dlova, N., additional, Faye, O., additional, Flohr, C., additional, Hsu, C., additional, Mavura, D., additional, Manuel, R. C., additional, Ramarozatovo, L. S., additional, Sendrasoa, F., additional, Wollenberg, A., additional, Postigo, J. A. Ruiz, additional, and Taïeb, A., additional

Published
2023
Full Text
View/download PDF

5. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge‐proven food allergy: A systematic review and meta‐analysis

Author

Christensen, M. O., primary, Barakji, Y. A., additional, Loft, N., additional, Khatib, C. M., additional, Egeberg, A., additional, Thomsen, S. F., additional, Silverberg, J. I., additional, Flohr, C., additional, Maul, J. T., additional, Schmid‐Grendelmeier, P., additional, Halling, A. S., additional, Vittrup, I., additional, and Thyssen, J. P., additional

Published
2023
Full Text
View/download PDF

6. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov

Author

Zitouni, J., primary, Bursztejn, A.C., additional, Belloni Fortina, A., additional, Beauchet, A., additional, Di Lernia, V., additional, Lesiak, A., additional, Thomas, J., additional, Topkarci, Z., additional, Murashkin, N., additional, Brzezinski, P., additional, Torres, T., additional, Chiriac, A., additional, Luca, C., additional, Mcpherson, T., additional, Akinde, M., additional, Maruani, A., additional, Epishev, R., additional, Vidaurri De La Cruz, H., additional, Luna, P., additional, Amy De La Breteque, M., additional, Lasek, A., additional, Bourrat, E., additional, Bachelerie, M., additional, Mallet, S., additional, Steff, M., additional, Bellissen, A., additional, Neri, I., additional, Zafiriou, E., additional, Van Den Reek, J., additional, Sonkoly, E., additional, Kupfer-Bessaguet, I., additional, Leducq, S., additional, Mahil, S., additional, Smith, C., additional, Flohr, C., additional, Bachelez, H., additional, and Mahé, E., additional

Published
2022
Full Text
View/download PDF

7. Facteurs prédictifs d’une poussée de psoriasis après une infection par le SARS-CoV-2 chez l’enfant

Author

Mahé, E., primary, Zitouni, J., additional, Di Lernia, V., additional, Belloni Fortina, A., additional, Lesiak, A., additional, Brzezinski, P., additional, Topkarci, Z., additional, Murashkin, N., additional, Torres, T., additional, Vidaurri De La Cruz, H., additional, Maruani, A., additional, Chiriac, A., additional, Mallet, S., additional, Kupfer-Bessaguet, I., additional, Sonkoly, E., additional, Bursztejn, A.C., additional, Van Den Reek, J., additional, Epishev, R., additional, Severino Freire, M., additional, Akinde, M., additional, Beauchet, A., additional, Luca, C., additional, Thomas, J., additional, Mcpherson, T., additional, Bachelerie, M., additional, Bourrat, E., additional, Bellissen, A., additional, Zafiriou, E., additional, Leducq, S., additional, Neri, I., additional, Luna, P., additional, Steff, M., additional, Sergeant, M., additional, Mahil, S., additional, Smith, C., additional, Flohr, C., additional, and Bachelez, H., additional

Published
2022
Full Text
View/download PDF

8. European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations

Author

Wollenberg, A., primary, Kinberger, M., additional, Arents, B., additional, Aszodi, N., additional, Avila Valle, G., additional, Barbarot, S., additional, Bieber, T., additional, Brough, H.A., additional, Calzavara Pinton, P., additional, Christen‐Zäch, S., additional, Deleuran, M., additional, Dittmann, M., additional, Dressler, C., additional, Fink‐Wagner, A.H., additional, Fosse, N., additional, Gáspár, K., additional, Gerbens, L., additional, Gieler, U., additional, Girolomoni, G., additional, Gregoriou, S., additional, Mortz, C.G., additional, Nast, A., additional, Nygaard, U., additional, Redding, M., additional, Rehbinder, E.M., additional, Ring, J., additional, Rossi, M., additional, Serra‐Baldrich, E., additional, Simon, D., additional, Szalai, Z.Z., additional, Szepietowski, J.C., additional, Torrelo, A., additional, Werfel, T., additional, and Flohr, C., additional

Published
2022
Full Text
View/download PDF

9. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries

Author

Vermeulen, FM, Gerbens, LAA, Bosma, AL, Apfelbacher, CJ, Irvine, AD, Arents, BWM, Barbarot, S, Deleuran, M, Eichenfield, LF, Manca, A, Schmitt, J, Vestergaard, C, Wall, D, Weidinger, S, Middelkamp‐Hup, MA, Spuls, PI, Flohr, C, and Taskforce, the International TREAT Registry

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, Skin, Adult, Advisory Committees, Aftercare, Child, Consensus, Datasets as Topic, Dermatitis, Atopic, Dermatologic Agents, Humans, Phototherapy, Prospective Studies, Registries, Severity of Illness Index, Treatment Outcome, International TREAT Registry Taskforce, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited. Such data must come from well-designed prospective patient registries. Standardization of data collection is needed for direct comparisons and data pooling.ObjectivesTo reach a consensus on how and when to measure the previously defined domain items of the TREatment of ATopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult patients with AE.MethodsProposals for the measurement instruments were based on recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, systematic reviews of the literature and expert opinions. The proposals were discussed at three face-to-face consensus meetings, one teleconference and via e-mail. The frequency of follow-up visits was determined by an expert survey.ResultsA total of 16 experts from seven countries participated in the 'how to measure' consensus process and 12 external experts were consulted. A consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined.ConclusionsThis core dataset for national AE research registries will aid in the comparability and pooling of data across centres and country borders, and enables international collaboration to assess the long-term effectiveness and safety of phototherapy and systemic therapy used in patients with AE. What's already known about this topic? Comparable, real-life and long-term data on the effectiveness and safety of phototherapy and systemic therapy in patients with atopic eczema (AE) are needed. There is a high diversity of outcomes and instruments used in AE research, which require harmonization to enhance comparability and allow data pooling. What does this study add? Our taskforce has reached international consensus on how and when to measure core domain items for national AE research registries. This core dataset is now available for use by researchers worldwide and will aid in the collection of unified data. What are the clinical implications of this work? The data collected through this core dataset will help to gain better insights into the long-term effectiveness and safety of phototherapy and systemic therapy in AE and will provide important information for clinical practice. Standardization of such data collection at the national level will also allow direct data comparisons and pooling across country borders (e.g. in the analysis of treatment-related adverse events that require large patient numbers).

Published
2019

10. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

Author

Wollenberg, A., primary, Kinberger, M., additional, Arents, B., additional, Aszodi, N., additional, Avila Valle, G., additional, Barbarot, S., additional, Bieber, T., additional, Brough, H.A., additional, Calzavara Pinton, P., additional, Christen‐Zäch, S., additional, Deleuran, M., additional, Dittmann, M., additional, Dressler, C., additional, Fink‐Wagner, A.H., additional, Fosse, N., additional, Gáspár, K., additional, Gerbens, L., additional, Gieler, U., additional, Girolomoni, G., additional, Gregoriou, S., additional, Mortz, C.G., additional, Nast, A., additional, Nygaard, U., additional, Redding, M., additional, Rehbinder, E.M., additional, Ring, J., additional, Rossi, M., additional, Serra‐Baldrich, E., additional, Simon, D., additional, Szalai, Z.Z., additional, Szepietowski, J.C., additional, Torrelo, A., additional, Werfel, T., additional, and Flohr, C., additional

Published
2022
Full Text
View/download PDF

11. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries

Author

Gerbens, LAA, Apfelbacher, CJ, Irvine, AD, Barbarot, S, Booij, RJ, Boyce, AE, Deleuran, M, Eichenfield, LF, Hof, MH, Middelkamp‐Hup, MA, Roberts, A, Schmitt, J, Vestergaard, C, Wall, D, Weidinger, S, Williamson, PR, Flohr, C, Spuls, PI, and Taskforce, the international TREAT Registry

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Cancer, Clinical Research, Advisory Committees, Consensus, Delphi Technique, Dermatitis, Atopic, Humans, Immunologic Factors, International Cooperation, Photochemotherapy, Photosensitizing Agents, Registries, Stakeholder Participation, Treatment Outcome, international TREAT Registry Taskforce, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BACKGROUND:Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE) is scarce, despite frequent and often off-label use. Patient registries provide valuable evidence for the effects of treatments under real-world conditions that can inform treatment guidelines, give the opportunity for health economic evaluation and the evaluation of quality of care, as well as pharmacogenetic and dynamic research, which cannot be adequately addressed in clinical trials. OBJECTIVES:The TREatment of ATopic eczema (TREAT) Registry Taskforce aims to seek international consensus on a core set of domains and items ('what to measure') for AE research registries, using a Delphi approach. METHODS:Participants from six stakeholder groups were included: doctors, nurses, nonclinical researchers, patients, industry and regulatory body representatives. The eDelphi comprised three sequential online rounds, requesting participants to rate the importance of each proposed domain item. Participants could add domain items to the proposed list in round 1. A final consensus meeting was held to ratify the core set. RESULTS:Participants (n = 479) from 36 countries accessed the eDelphi platform, of whom 86%, 79% and 74% completed rounds 1, 2 and 3, respectively. At the face-to-face consensus meeting attended by 42 participants the final core set was established containing 19 domains with 69 domain items (49 baseline and 20 follow-up items). CONCLUSIONS:This core set of domains and items to be captured by national AE systemic therapy registries will standardize data collection and thereby allow direct comparability across registries and facilitate data pooling between countries. Ultimately, it will provide greater insight into the effectiveness, safety and cost-effectiveness of photo- and systemic immunomodulatory therapies.

Published
2019

12. Systematic review of atopic dermatitis disease definition in studies using routinely collected health data

Author

Dizon, MP, Yu, AM, Singh, RK, Wan, J, Chren, M‐M, Flohr, C, Silverberg, JI, Margolis, DJ, Langan, SM, and Abuabara, K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Brain Disorders, Good Health and Well Being, Adult, Algorithms, Child, Clinical Coding, Data Collection, Dermatitis, Atopic, Electronic Health Records, Female, Humans, Male, Prevalence, Terminology as Topic, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundRoutinely collected electronic health data obtained for administrative and clinical purposes are increasingly used to study atopic dermatitis (AD). Methods for identifying AD patients in routinely collected electronic health data differ, and it is unknown how this might affect study results.ObjectivesTo evaluate how patients with AD have been identified in studies using routinely collected electronic health data, to determine whether these methods were validated and to estimate how the method for identifying patients with AD affected variability in prevalence estimates.MethodsWe systematically searched PubMed, Embase and Web of Science for studies using routinely collected electronic health data that reported on AD as a primary outcome. Studies of localized AD and other types of dermatitis were excluded. The protocol for this review was registered in PROSPERO (CRD42016037968).ResultsIn total, 59 studies met eligibility criteria. Medical diagnosis codes for inclusion and exclusion, number of occasions of a code, type of provider associated with a code and prescription data were used to identify patients with AD. Only two studies described validation of their methods and no study reported on disease severity. Prevalence estimates ranged from 0·18% to 38·33% (median 4·91%) and up to threefold variation in prevalence was introduced by differences in the method for identifying patients with AD.ConclusionsThis systematic review highlights the need for clear reporting of methods for identifying patients with AD in routinely collected electronic health data to allow for meaningful interpretation and comparison of results.

Published
2018

13. Requirements and expectations of high‐quality biomarkers for atopic dermatitis and psoriasis in 2021—a two‐round Delphi survey among international experts

Author

Ziehfreund, S., primary, Tizek, L., additional, Hangel, N., additional, Fritzsche, M.‐C., additional, Weidinger, S., additional, Smith, C., additional, Bryce, P.J., additional, Greco, D., additional, van den Bogaard, E.H., additional, Flohr, C., additional, Rastrick (UCB), J., additional, Eyerich, S., additional, Buyx, A., additional, Conrad, C., additional, Eyerich, K., additional, and Zink, A., additional

Published
2022
Full Text
View/download PDF

16. Randomized controlled pilot trial with ion‐exchange water softeners to prevent eczema (SOFTER trial)

Author

Jabbar‐Lopez, Z. K., primary, Ezzamouri, B., additional, Briley, A., additional, Greenblatt, D., additional, Gurung, N., additional, Chalmers, J. R., additional, Thomas, K. S., additional, Frost, T., additional, Kezic, S., additional, Common, J. E. A., additional, Danby, S., additional, Cork, M. J., additional, Peacock, J. L., additional, and Flohr, C., additional

Published
2021
Full Text
View/download PDF

17. Phototherapy for atopic dermatitis: A survey of European practice.

Author

Steyn, M., Gerbens, L. A. A., Spuls, P. I., Mashayekhi, S., Deleuran, M., Barbarot, S., Wollenberg, A., Ferguson, J., Ibbotson, S., and Flohr, C.

Subjects
ATOPIC dermatitis, PHOTOTHERAPY, CHILD patients, PHOTOCHEMOTHERAPY, RANDOMIZED controlled trials
Abstract

Background: Phototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost‐effectiveness and short‐ and long‐term safety with real‐life usage is weak. Objectives: We established a taskforce to examine how phototherapy is currently being used as a treatment for AD across the United Kingdom and Europe to inform our understanding and guide future research into management of patients with AD using UV‐based phototherapies. Methods: An anonymous electronic multiple‐response survey exploring phototherapy prescribing practices and experience of phototherapy modalities was developed by the study authors and sent to members of phototherapy networks from the United Kingdom and Europe. Responses were received between February and July 2021. Results: About 144 respondents from 27 European countries completed the survey. NBUVB was the most widely used [n = 138 (96%)]. Home‐based NBUVB was available in 8/27 countries (25/144 respondents, 17%). Oral psoralen‐UVA (PUVA) was more widely available than bath PUVA (n = 106, 74% vs. n = 60, 42%) and used mainly in adult patients. 49/144 (34%) of respondents had access to UVA1. Phototherapy would be considered instead of systemic treatment in 96% of adults and 82% of children for NBUVB, versus 40% of adults and 3% of children for PUVA. Starting doses, standard dosing increments, length of treatment courses, lifetime limits for treatments and thresholds for performing annual skin assessments varied between responders. Conclusions: NBUVB was the most widely used phototherapy for AD in adult and paediatric patients, while PUVA and UVA1 were less used. Prescribing practices varied considerably, highlighting the lack of consensus practice in many different aspects of phototherapy for the treatment of AD in children and adults. This indicates that further studies are required to determine optimal phototherapeutic regimens for AD and informs our understanding of parameters that should be included in future high‐quality randomized controlled trials (RCT) of phototherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines*

Author

Haw, W.Y., primary, Al‐Janabi, A., additional, Arents, B.W.M., additional, Asfour, L., additional, Exton, L.S., additional, Grindlay, D., additional, Khan, S.S., additional, Manounah, L., additional, Yen, H., additional, Chi, C.‐C., additional, Zuuren, E.J., additional, Flohr, C., additional, and Yiu, Z.Z.N., additional

Published
2021
Full Text
View/download PDF

19. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Author

Ring, J., primary, Worm, M., additional, Wollenberg, A., additional, Thyssen, J.P., additional, Jakob, T., additional, Klimek, L., additional, Bangert, C., additional, Barbarot, S., additional, Bieber, T., additional, Bruin‐Weller, M.S., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Cork, M., additional, Darsow, U., additional, Flohr, C., additional, Fölster‐Holst, R., additional, Gelmetti, C., additional, Gieler, U., additional, Gutermuth, J., additional, Heratizadeh, A., additional, Hijnen, D.J., additional, Kobyletzki, L.B., additional, Kunz, B., additional, Paul, C., additional, De Raeve, L., additional, Seneschal, J., additional, Simon, D., additional, Spuls, P.I., additional, Stalder, J.F., additional, Svensson, A., additional, Szalai, Z., additional, Taieb, A., additional, Torrelo, A., additional, Trzeciak, M., additional, Vestergaard, C., additional, Werfel, T., additional, Weidinger, S., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

20. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Barbarot, S., additional, de Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, von Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Christen‐Zaech, S., additional, Hijnen, D.J., additional, Gieler, U., additional, Gutermuth, J., additional, Bangert, C., additional, Spuls, P.I., additional, Kunz, B., additional, Ring, J., additional, Wollenberg, A., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

27. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Deleuran, M., additional, Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Barbarot, S., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Cristen‐Zaech, S., additional, Hijnen, D., additional, Gieler, U., additional, Ring, J., additional, and Wollenberg, A., additional

Published
2020
Full Text
View/download PDF

28. 特应性湿疹的治疗 (TREAT) 登记工作组:比较 Dupilumab 与其他全身药物治疗中度至重度湿疹安全性的方法

Author

Bosma, A.L., primary, Spuls, P.I., additional, Garcia‐Doval, I., additional, Naldi, L., additional, Prieto‐Merino, D., additional, Tesch, F., additional, Apfelbacher, C.J., additional, Arents, B.W.M., additional, Barbarot, S., additional, Baselga, E., additional, Deleuran, M., additional, Eichenfield, L.F., additional, Gerbens, L.A.A., additional, Irvine, A.D., additional, Manca, A., additional, Mendes‐Bastos, P., additional, Middelkamp‐Hup, M.A., additional, Roberts, A., additional, Seneschal, J., additional, Svensson, Å., additional, Thyssen, J.P., additional, Torres, T., additional, Vermeulen, F.M., additional, Vestergaard, C., additional, Kobyletzki, L.B., additional, Wall, D., additional, Weidinger, S., additional, Schmit, J., additional, and Flohr, C., additional

Published
2020
Full Text
View/download PDF

30. TREatment of ATopic eczema (TREAT) Registry Taskforce: method for comparing the safety of dupilumab with other systemic therapies for moderate‐to‐severe eczema

Author

Bosma, A.L., primary, Spuls, P.I., additional, Garcia‐Doval, I., additional, Naldi, L., additional, Prieto‐Merino, D., additional, Tesch, F., additional, Apfelbacher, C.J., additional, Arents, B.W.M., additional, Barbarot, S., additional, Baselga, E., additional, Deleuran, M., additional, Eichenfield, L.F., additional, Gerbens, L.A.A., additional, Irvine, A.D., additional, Manca, A., additional, Mendes‐Bastos, P., additional, Middelkamp‐Hup, M.A., additional, Roberts, A., additional, Seneschal, J., additional, Svensson, Å., additional, Thyssen, J.P., additional, Torres, T., additional, Vermeulen, F.M., additional, Vestergaard, C., additional, Kobyletzki, L.B., additional, Wall, D., additional, Weidinger, S., additional, Schmitt, J., additional, and Flohr, C., additional

Published
2020
Full Text
View/download PDF

31. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

Author

Wollenberg, A., primary, Flohr, C., additional, Simon, D., additional, Cork, M.J., additional, Thyssen, J.P., additional, Bieber, T., additional, de Bruin‐Weller, M.S., additional, Weidinger, S., additional, Deleuran, M., additional, Taieb, A., additional, Paul, C., additional, Trzeciak, M., additional, Werfel, T., additional, Seneschal, J., additional, Barbarot, S., additional, Darsow, U., additional, Torrelo, A., additional, Stalder, J.‐F., additional, Svensson, Å., additional, Hijnen, D., additional, Gelmetti, C., additional, Szalai, Z., additional, Gieler, U., additional, De Raeve, L., additional, Kunz, B., additional, Spuls, P., additional, von Kobyletzki, L.B., additional, Fölster‐Holst, R., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Heratizadeh, A., additional, Ring, J., additional, and Vestergaard, C., additional

Published
2020
Full Text
View/download PDF

35. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

Author

Alexander, H., primary, Paller, A.S., additional, Traidl‐Hoffmann, C., additional, Beck, L.A., additional, De Benedetto, A., additional, Dhar, S., additional, Girolomoni, G., additional, Irvine, A.D., additional, Spuls, P., additional, Su, J., additional, Thyssen, J.P., additional, Vestergaard, C., additional, Werfel, T., additional, Wollenberg, A., additional, Deleuran, M., additional, and Flohr, C., additional

Published
2019
Full Text
View/download PDF

36. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

Author

Bosma, A.L., primary, Spuls, P.I., additional, Garcia‐Doval, I., additional, Naldi, L., additional, Prieto‐Merino, D., additional, Tesch, F., additional, Apfelbacher, C.J., additional, Arents, B.W.M., additional, Barbarot, S., additional, Baselga, E., additional, Deleuran, M., additional, Eichenfield, L.F., additional, Gerbens, L.A.A., additional, Irvine, A.D., additional, Manca, A., additional, Mendes‐Bastos, P., additional, Middelkamp‐Hup, M.A., additional, Roberts, A., additional, Seneschal, J., additional, Svensson, Å., additional, Thyssen, J.P., additional, Torres, T., additional, Vermeulen, F.M., additional, Vestergaard, C., additional, Kobyletzki, L.B., additional, Wall, D., additional, Weidinger, S., additional, Schmitt, J., additional, and Flohr, C., additional

Published
2019
Full Text
View/download PDF

39. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Author

Vestergaard, C., primary, Wollenberg, A., additional, Barbarot, S., additional, Christen‐Zaech, S., additional, Deleuran, M., additional, Spuls, P., additional, Flohr, C., additional, Trzeciak, M., additional, von Kobyletzki, L., additional, Seneschal, J., additional, Paul, C., additional, Bieber, T., additional, Werfel, T., additional, Fölster‐Holst, R., additional, Darsow, U., additional, Gieler, U., additional, Svensson, Å., additional, Cork, M., additional, Stalder, J.‐F., additional, De Raeve, L., additional, Kunz, B., additional, Simon, D., additional, Chernyshov, P., additional, Hijnen, D., additional, Gelmetti, C., additional, Ring, J., additional, Taieb, A., additional, de Bruin‐Weller, M., additional, and Thyssen, J.P., additional

Published
2019
Full Text
View/download PDF

40. First Update of the Living European Guideline (EuroGuiDerm) on Atopic Eczema

Author

Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Barbarot, S, Bieber, T, Brough, H A, Pinton, P Calzavara, Christen-Zaech, S, Deleuran, M, Dittmann, M, Fosse, N, Gáspár, K, Gerbens, L A A, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, C G, Nast, A, Nygaard, U, Rehbinder, E M, Ring, J, Rossi, M, Roxburgh, C, Serra-Baldrich, E, Simon, D, Szalai, Z Z, Szepietowski, J C, Torrelo, A, Werfel, T, and Flohr, C

Subjects
610 Medicine & health
Published
2023
Full Text
View/download PDF

42. Are Environmental Factors for Atopic Eczema in ISAAC Phase Three due to Reverse Causation?

Author

Rutter, Charlotte E., primary, Silverwood, Richard J., additional, Williams, Hywel C., additional, Ellwood, Philippa, additional, Asher, Innes, additional, Garcia-Marcos, Luis, additional, Strachan, David P., additional, Pearce, Neil, additional, Langan, Sinéad M., additional, Aït-Khaled, N., additional, Anderson, H.R., additional, Asher, M.I., additional, Beasley, R., additional, Björkstén, B., additional, Brunekreef, B., additional, Crane, J., additional, Ellwood, P., additional, Flohr, C., additional, Foliaki, S., additional, Forastiere, F., additional, García-Marcos, L., additional, Keil, U., additional, Lai, C.K.W., additional, Mallol, J., additional, Mitchell, E.A., additional, Montefort, S., additional, Odhiambo, J., additional, Pearce, N., additional, Robertson, C.F., additional, Stewart, A.W., additional, Strachan, D., additional, von Mutius, E., additional, Weiland, S.K., additional, Weinmayr, G., additional, Williams, H.C., additional, Wong, G., additional, Clayton, T.O., additional, Ellwood, E., additional, Baena-Cagnani, C.E., additional, Gómez, M., additional, Howitt, M.E., additional, Weyler, J., additional, Pinto-Vargas, R., additional, Petrolera de Salud, Caja, additional, Cunha, A.J. D.A., additional, de Freitas Souza, L., additional, Kuaban, C., additional, Ferguson, A., additional, Rennie, D., additional, Standring, P., additional, Aguilar, P., additional, Amarales, L., additional, Benavides, L.A., additional, Contreras, A., additional, Chen, Y.-Z., additional, Kunii, O., additional, Pan, Q. Li, additional, Zhong, N.-S., additional, Aristizábal, G., additional, Cepeda, A.M., additional, Ordoñez, G.A., additional, Bustos, C., additional, Riikjärv, M.-A., additional, Melaku, K., additional, Sa’aga-Banuve, R., additional, Pekkanen, J., additional, Hypolite, I.E., additional, Novák, Z., additional, Zsigmond, G., additional, Awasthi, S., additional, Bhave, S., additional, Hanumante, N.M., additional, Jain, K.C., additional, Joshi, M.K., additional, Mantri, S.N., additional, Pherwani, A.V., additional, Rego, S., additional, Sabir, M., additional, Salvi, S., additional, Setty, G., additional, Sharma, S.K., additional, Singh, V., additional, Sukumaran, T., additional, Suresh Babu, P.S., additional, Kartasasmita, C.B., additional, Konthen, P., additional, Suprihati, W., additional, Masjedi, M.R., additional, Steriu, A., additional, Koffi, B.N., additional, Odajima, H., additional, al-Momen, J.A., additional, Imanalieva, C., additional, Kudzyte, J., additional, Quah, B.S., additional, Teh, K.H., additional, Baeza-Bacab, M., additional, Barragán-Meijueiro, M., additional, Del-Río-Navarro, B.E., additional, García-Almaráz, R., additional, González-Díaz, S.N., additional, Linares-Zapién, F.J., additional, Merida-Palacio, J.V., additional, Ramírez-Chanona, N., additional, Romero-Tapia, S., additional, Romieu, I., additional, Bouayad, Z., additional, MacKay, R., additional, Moyes, C., additional, Pattemore, P., additional, Onadeko, B.O., additional, Cukier, G., additional, Chiarella, P., additional, Cua-Lim, F., additional, Brêborowicz, A., additional, Solé, D., additional, Sears, M., additional, Aguirre, V., additional, Barba, S., additional, Shah, J., additional, Baratawidjaja, K., additional, Nishima, S., additional, de Bruyne, J., additional, Tuuau-Potoi, N., additional, Lai, C.K., additional, Lee, B.W., additional, El Sony, A., additional, and Anderson, R., additional

Published
2019
Full Text
View/download PDF

47. BSPD guidelines for treatment of IH with propranolol

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

48. 使用普萘洛尔治疗IH的BSPD指南

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

49. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines

Author

Solman, L., primary, Glover, M., additional, Beattie, P.E., additional, Buckley, H., additional, Clark, S., additional, Gach, J.E., additional, Giardini, A., additional, Helbling, I., additional, Hewitt, R.J., additional, Laguda, B., additional, Langan, S.M., additional, Martinez, A.E., additional, Murphy, R., additional, Proudfoot, L., additional, Ravenscroft, J., additional, Shahidullah, H., additional, Shaw, L., additional, Syed, S.B., additional, Wells, L., additional, and Flohr, C., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results